- Home
- FRT vs VRNA Comparison
FRT vs VRNA Comparison
Compare FRT & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRT
- VRNA
- Stock Information
- Founded
- FRT 1962
- VRNA 2005
- Country
- FRT United States
- VRNA United Kingdom
- Employees
- FRT N/A
- VRNA N/A
- Industry
- FRT Real Estate Investment Trusts
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- FRT Real Estate
- VRNA Health Care
- Exchange
- FRT Nasdaq
- VRNA Nasdaq
- Market Cap
- FRT 8.2B
- VRNA 7.8B
- IPO Year
- FRT N/A
- VRNA 2017
- Fundamental
- Price
- FRT $95.45
- VRNA $92.20
- Analyst Decision
- FRT Buy
- VRNA Strong Buy
- Analyst Count
- FRT 13
- VRNA 7
- Target Price
- FRT $114.46
- VRNA $97.57
- AVG Volume (30 Days)
- FRT 617.7K
- VRNA 1.4M
- Earning Date
- FRT 07-31-2025
- VRNA 08-07-2025
- Dividend Yield
- FRT 4.60%
- VRNA N/A
- EPS Growth
- FRT 23.89
- VRNA N/A
- EPS
- FRT 3.47
- VRNA N/A
- Revenue
- FRT $1,223,588,000.00
- VRNA $118,535,000.00
- Revenue This Year
- FRT $5.26
- VRNA $891.79
- Revenue Next Year
- FRT $5.59
- VRNA $78.94
- P/E Ratio
- FRT $27.55
- VRNA N/A
- Revenue Growth
- FRT 6.05
- VRNA N/A
- 52 Week Low
- FRT $80.65
- VRNA $14.14
- 52 Week High
- FRT $118.34
- VRNA $94.45
- Technical
- Relative Strength Index (RSI)
- FRT 49.32
- VRNA 78.05
- Support Level
- FRT $94.75
- VRNA $82.18
- Resistance Level
- FRT $96.66
- VRNA $93.74
- Average True Range (ATR)
- FRT 1.49
- VRNA 3.21
- MACD
- FRT -0.08
- VRNA 0.89
- Stochastic Oscillator
- FRT 34.05
- VRNA 92.52
About FRT Federal Realty Investment Trust
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 102 properties, which includes 26.8 million square feet of retail space and over 3,100 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.